Utility of ankyrin 3 as a prognostic marker in androgen-receptor-positive breast cancer

[1]  I. Ellis,et al.  Clinicopathological and prognostic significance of Ras association and pleckstrin homology domains 1 (RAPH1) in breast cancer , 2018, Breast Cancer Research and Treatment.

[2]  Kylie L. Gorringe,et al.  Clinical and biological roles of Kelch-like family member 7 in breast cancer: a marker of poor prognosis , 2018, Breast Cancer Research and Treatment.

[3]  I. Ellis,et al.  Mediator complex (MED) 7: a biomarker associated with good prognosis in invasive breast cancer, especially ER+ luminal subtypes , 2018, British Journal of Cancer.

[4]  Peter Schmid,et al.  Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  J. Cuzick,et al.  De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  Hongwei Gao,et al.  Targeting Androgen Receptor in Treating HER2 Positive Breast Cancer , 2017, Scientific Reports.

[7]  M. Kurosumi,et al.  Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index , 2017, BMC Cancer.

[8]  G. Ball,et al.  Prognostic stratification of oestrogen receptor‐positive HER2‐negative lymph node‐negative class of breast cancer , 2017, Histopathology.

[9]  The Gene Ontology Consortium,et al.  Expansion of the Gene Ontology knowledgebase and resources , 2016, Nucleic Acids Res..

[10]  Z. Gatalica,et al.  Apocrine carcinoma of the breast: A brief update on the molecular features and targetable biomarkers. , 2016, Bosnian journal of basic medical sciences.

[11]  The Gene Ontology Consortium.  Expansion of the Gene Ontology knowledgebase and resources , 2016, Nucleic Acids Res..

[12]  D. Amadori,et al.  Androgen receptor signaling pathways as a target for breast cancer treatment. , 2016, Endocrine-related cancer.

[13]  M. Alshalalfa,et al.  Ankyrin G expression is associated with androgen receptor stability, invasiveness, and lethal outcome in prostate cancer patients , 2016, Journal of Molecular Medicine.

[14]  I. Ellis,et al.  Prognostic significance of androgen receptor expression in invasive breast cancer: transcriptomic and protein expression analysis , 2016, Breast Cancer Research and Treatment.

[15]  A. Shah,et al.  Regulation of endothelial homeostasis, vascular development and angiogenesis by the transcription factor ERG , 2016, Vascular pharmacology.

[16]  N. Rosenfeld,et al.  The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes , 2016, Nature Communications.

[17]  K. Wisinski,et al.  Role of the androgen receptor in triple-negative breast cancer. , 2016, Clinical advances in hematology & oncology : H&O.

[18]  P. Neven,et al.  Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer† , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  R. Gelber,et al.  Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  Takashi Suzuki,et al.  Increased androgen receptor activity and cell proliferation in aromatase inhibitor-resistant breast carcinoma , 2014, The Journal of Steroid Biochemistry and Molecular Biology.

[21]  S. Vowler,et al.  HES6 drives a critical AR transcriptional programme to induce castration-resistant prostate cancer through activation of an E2F1-mediated cell cycle network , 2014, EMBO molecular medicine.

[22]  G. Ball,et al.  Nottingham Prognostic Index Plus (NPI+): a modern clinical decision making tool in breast cancer , 2014, British Journal of Cancer.

[23]  R. Alhajj,et al.  Interrogation of ERG gene rearrangements in prostate cancer identifies a prognostic 10‐gene signature with relevant implication to patients' clinical outcome , 2014, BJU international.

[24]  I. Tannock,et al.  Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis. , 2014, Journal of the National Cancer Institute.

[25]  G. Ball,et al.  Identification of key clinical phenotypes of breast cancer using a reduced panel of protein biomarkers , 2013, British Journal of Cancer.

[26]  Andres Forero,et al.  Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer , 2013, Clinical Cancer Research.

[27]  Funda Meric-Bernstam,et al.  Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes , 2013, Clinical Cancer Research.

[28]  N. Maitland,et al.  Monoallelic expression of TMPRSS2/ERG in prostate cancer stem cells , 2013, Nature Communications.

[29]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[30]  Klemens Vierlinger,et al.  Meta-Analysis of Gene Expression Signatures Defining the Epithelial to Mesenchymal Transition during Cancer Progression , 2012, PloS one.

[31]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[32]  S. Fuqua,et al.  The Role of Androgen Receptor in Breast Cancer. , 2012, Drug discovery today. Disease mechanisms.

[33]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[34]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[35]  A. Weeraratna,et al.  The growth response to androgen receptor signaling in ERα-negative human breast cells is dependent on p21 and mediated by MAPK activation , 2012, Breast Cancer Research.

[36]  X. Chen,et al.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. , 2011, The Journal of clinical investigation.

[37]  A. Naderi,et al.  A feedback loop between androgen receptor and ERK signaling in estrogen receptor-negative breast cancer. , 2011, Neoplasia.

[38]  G. Ball,et al.  RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype , 2011, Breast Cancer Research and Treatment.

[39]  I. Ellis,et al.  Clinicopathologic and molecular significance of phospho-Akt expression in early invasive breast cancer , 2011, Breast Cancer Research and Treatment.

[40]  Zhaohui S. Qin,et al.  An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. , 2010, Cancer cell.

[41]  I. Ellis,et al.  PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis , 2010, Breast Cancer Research and Treatment.

[42]  C. Bondy,et al.  Androgens and the breast , 2009, Breast Cancer Research.

[43]  I. Ellis,et al.  Triple-Negative Breast Cancer: Distinguishing between Basal and Nonbasal Subtypes , 2009, Clinical Cancer Research.

[44]  S. Hayashi,et al.  Estrogen signaling pathway and hormonal therapy , 2008, Breast cancer.

[45]  G. Ball,et al.  Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance. , 2008, European journal of cancer.

[46]  K. Dolinski,et al.  Use and misuse of the gene ontology annotations , 2008, Nature Reviews Genetics.

[47]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[48]  G. Glinsky,et al.  Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. , 2005, The Journal of clinical investigation.

[49]  S Miyano,et al.  Open source clustering software. , 2004, Bioinformatics.

[50]  M. Daly,et al.  PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes , 2003, Nature Genetics.

[51]  M. Ashburner,et al.  Gene Ontology: tool for the unification of biology , 2000, Nature Genetics.

[52]  D. Botstein,et al.  Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[53]  J. Morrow,et al.  The role of ankyrin and spectrin in membrane transport and domain formation. , 1998, Current opinion in cell biology.

[54]  S Detre,et al.  A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. , 1995, Journal of clinical pathology.

[55]  Vann Bennett,et al.  From anemia to cerebellar dysfunction , 1993 .

[56]  V. Bennett,et al.  From anemia to cerebellar dysfunction. A review of the ankyrin gene family. , 1993, European journal of biochemistry.

[57]  V. Bennett,et al.  Ankyrins. Adaptors between diverse plasma membrane proteins and the cytoplasm. , 1992, The Journal of biological chemistry.

[58]  E B Cox,et al.  Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. , 1985, Archives of pathology & laboratory medicine.